{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:22:25Z","timestamp":1789428145127,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.09.011","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T23:41:07Z","timestamp":1632354067000},"page":"312-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers"],"prefix":"10.1016","volume":"163","author":[{"given":"G.","family":"Contos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.09.011_bb0005","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/EDBK_237967","article-title":"Immunotherapy in gynecologic cancers: what we know now and where we are headed","volume":"39","author":"Levinson","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Edu. Book"},{"key":"10.1016\/j.ygyno.2021.09.011_bb0010","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1200\/JCO.2016.34.15_suppl.5516","article-title":"ADXS11-001 immunotherapy in squamous or non-squamous persistent\/recurrent metastatic cervical cancer. Results from stage I of the phase II GOG\/NRG0265 study","volume":"34","author":"Huh","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.011_bb0015","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27817","article-title":"Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy","volume":"3","author":"Champiat","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2021.09.011_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","article-title":"A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now","volume":"54","author":"Bellmunt","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.011_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"6230","key":"10.1016\/j.ygyno.2021.09.011_bb0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"6286","key":"10.1016\/j.ygyno.2021.09.011_bb0035","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \u201ccancer immunogram\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"issue":"10183","key":"10.1016\/j.ygyno.2021.09.011_bb0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.011_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0050","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2017.35.15_suppl.5513","article-title":"Pembrolizumab in patients (pts) with PD-L1\u2013positive (PD-L1 +) advanced ovarian cancer: updated analysis of KEYNOTE028","volume":"35","author":"Varga","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0055","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2018.36.15_suppl.5511","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE 100 study","volume":"36","author":"Matulonis","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0060","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2018.36.15_suppl.5522","article-title":"Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 Keynote 158 study","volume":"36","author":"Chung","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6349","key":"10.1016\/j.ygyno.2021.09.011_bb0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ygyno.2021.09.011_bb0070","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.011_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2019.11.035","article-title":"Immune checkpoint expression, microsatellite instability, and mutational burden: identifying immune biomarker phenotypes in uterine cancer","volume":"156","author":"Jones","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2021.09.011_bb0080","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol. Prevent. Biomark."},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.011_bb0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ygyno.2010.04.015","article-title":"The prognostic significance of the triple negative phenotype in endometrial cancer","volume":"118","author":"Kothari","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"54","key":"10.1016\/j.ygyno.2021.09.011_bb0090","doi-asserted-by":"crossref","first-page":"92890","DOI":"10.18632\/oncotarget.21641","article-title":"Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology","volume":"8","author":"Hecking","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.011_bb0095","article-title":"PD-1 and PD-L1 expression in 1599 gynecological malignancies-implications for immunotherapy","volume":"137","author":"Herzog","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.011_bb0100","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.011_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0110","author":"FDA label for Pembrolizumab"},{"key":"10.1016\/j.ygyno.2021.09.011_bb0115","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0120","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0125","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumorinfiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2021.09.011_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0135","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN solid tumor phase 1b trial: safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0140","doi-asserted-by":"crossref","first-page":"871P","DOI":"10.1093\/annonc\/mdw374.18","article-title":"Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)","volume":"27","author":"Infante","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0145","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5612","article-title":"Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer","volume":"34","author":"Wehnham","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0150","series-title":"Presented at: International Gynecologic Cancer Society Meeting. Kyoto, Japan","article-title":"Abstract OC11: Randomized phase 2 trial of nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG study","author":"Burger","year":"2018"},{"key":"10.1016\/j.ygyno.2021.09.011_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy285.146","article-title":"A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer","volume":"29","author":"Liu","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0160","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ijc.26094","article-title":"VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2","volume":"130","author":"Ziogas","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.011_bb0165","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0170","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2019.04.045","article-title":"A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer","volume":"154","author":"Friedman","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.011_bb0180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovic","year":"2017","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ygyno.2021.09.011_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","article-title":"A comprehensive immunologic portrait of triple-negative breast cancer","volume":"11","author":"Liu","year":"2018","journal-title":"Transl. Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2021.09.011_bb0190","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1200\/JCO.2006.06.2489","article-title":"Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment","volume":"24","author":"Murugaesu","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.09.011_bb0195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer research network study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:50Z","timestamp":1758772730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013809"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}